Delgocitinib

Chronic hand eczema (CHE) is a complex condition with overlapping subtypes, making diagnosis and treatment challenging. Traditional treatments like steroids can worsen symptoms, but JAK inhibitors like delgocitinib offer hope without impairing skin barrier. CHE significantly impacts quality of life, with limited FDA-approved treatments in the US. Recent studies highlight the need for better therapies and understanding of CHE's prevalence and burden.

LEO Pharma's delgocitinib, a potential EU-approved treatment for chronic hand eczema (CHE), received a positive CHMP opinion. Marketed as Anzupgo, it could be the first topical treatment for moderate to severe CHE, offering hope for patients with limited effective therapies. CHE significantly impacts quality of life, relationships, and work.

Germany debuts LEO Pharma's Anzupgo, the first topical treatment for chronic hand eczema (CHE), with a list price of €953.25. Anzupgo, a pan-JAK inhibitor, outperformed placebo in phase 3 trials, showing better symptom relief. LEO plans further launches, aiming for revenue growth from 2025.

Current CHE treatments either cause side effects or don't address underlying inflammation. New treatments like Sanofi and Regeneron's Dupixent, Asana BioSciences and Afecta Pharmaceuticals' molecules, and Leo Pharma's Anzupgo, which outperformed Toctino in trials, aim to fill this gap, focusing on safety and quality of life.

Another market opens for Leo Pharma's Anzupgo, treating moderate-to-severe chronic hand eczema.

LEO Pharma Inc. announced FDA acceptance of a New Drug Application for delgocitinib cream 20 mg/g (2%) for treating moderate to severe Chronic Hand Eczema (CHE) in adults, marking progress towards addressing unmet needs. The European Commission also approved the cream in the EU. Delgocitinib cream, a topical pan-JAK inhibitor, showed efficacy in phase 3 trials, offering a potential new treatment option for CHE, a condition impacting quality of life significantly.

LEO Pharma Inc. announced FDA acceptance of a New Drug Application for delgocitinib cream 20 mg/g (2%) for treating moderate to severe Chronic Hand Eczema (CHE) in adults, marking progress towards addressing unmet needs in CHE treatment. The application is based on successful Phase 3 trials, with regulatory review expected to conclude by late 2025.

TRACE study: tralokinumab reduces genital AD severity & improves QoL within 3 months. Affordable at-home treatments like microneedling & benzoyl peroxide highlighted. Delgocitinib cream: safe option for chronic hand eczema. New sunscreen ingredients, physalis angulata & pycnogenol, prevent heat-induced pigmentation. CAB gel significantly reduces lesions in Hispanic patients.

At the EADV Congress, a poster presented patient experiences of chronic hand eczema (CHE) burden, based on interviews from the DELTA 1 trial. Patients reported significant impacts on daily activities, emotional well-being, and social functioning, with symptoms like cracking leading to pain and bleeding. The study highlighted the high disease burden on quality of life.